Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000

Frédéric B Piel, Andrew J Tatem, Zhuojie Huang, Sunetra Gupta, Thomas N Williams, David J Weatherall, Frédéric B Piel, Andrew J Tatem, Zhuojie Huang, Sunetra Gupta, Thomas N Williams, David J Weatherall

Abstract

Background: Changes in the geographical distribution of genetic disorders are often thought to happen slowly, especially when compared with infectious diseases. Whereas mutations, genetic drift, and natural selection take place over many generations, epidemics can spread through large populations within a few days or weeks. Nevertheless, population movements can interfere with these processes, and few studies have been done of their eff ect on genetic disorders. We aimed to investigate the eff ect of global migration on the distribution of the sickle-cell gene-the most common and clinically significant haemoglobin structural variant.

Methods: For each country, we extracted data from the World Bank’s Global Bilateral Migration Database about international human migrations between 1960 and 2000. We combined this information with evidence-based estimates of national HbS allele frequencies, generated within a Bayesian geostatistical framework, to analyse temporal changes in the net numbers of migrants, and classified countries with an index summarising these temporal trends.

Findings: The number of international migrants increased from 92.6 million in 1960, to 165.2 million in 2000. The estimated global number of migrants with HbS increased from about 1.6 million in 1960, to 3.6 million in 2000. This increase was largely due to an increase in the number of migrants from countries with HbS allele frequencies higher than 10%, from 3.1 million in 1960, to 14.2 million in 2000. Additionally, the mean number of countries of origin for each destination country increased from 70 (SE 46) in 1960, to 98 (48) in 2000, showing an increasing diversity in the network of international migrations between countries. Our index of change map shows a patchy distribution of the magnitude of temporal changes, with the highest positive and negative values scattered across all continents.

Interpretation: Global human population movements have had a substantial eff ect on the distribution of the HbS gene. Population movements can create a long-term burden on health-care systems. Our findings, which emphasise countries in which migration fluxes are changing the most, should increase awareness about the global burden of haemoglobinopathies and encourage policy makers to implement specific public health interventions, such as screening programmes and genetic counselling.

Funding: Wellcome Trust, European Research Council, Bill & Melinda Gates Foundation, National Institute of Allergy and Infectious Diseases-National Institutes of Health, the Research and Policy for Infectious Disease Dynamics program, Fogarty International Center.

Figures

Figure 1
Figure 1
Global trends in the number of international migrants and estimated migrants with HbS compared with the 1960s level We calculated the solid red line on the basis of median HbS frequency; the light red area represents the uncertainty on the basis of the 25% and 75% quantiles. HbS=sickle-cell haemoglobin.
Figure 2
Figure 2
Global trends in the average number of countries of origin per country of destination and the average estimated HbS frequency in the countries of origin per country of destination between 1960 and 2000 HbS=sickle-cell haemoglobin.
Figure 3
Figure 3
Estimated net migrations of individuals with HbS at the country level in 1960, 1970, 1980, 1990, and 2000 Countries in red correspond to those in which the estimated number of immigrants with HbS is higher than the estimated number of emigrants with HbS (sink countries). Countries in blue correspond to those in which the estimated number of immigrants with HbS is lower than the estimated number of emigrants with HbS (source countries). To aid comparisons, the same colour classes were used for all maps. HbS=sickle-cell haemoglobin.
Figure 4
Figure 4
Net numbers of migrants and estimated net number of migrants with HbS (based on the posterior median) relative to the 1960 level for selected countries in Africa (A), the Americas (B), Asia (C), and Europe (D), between 1960 and 2000 Countries on the left-hand side tend to be sinks of migrants with HbS (ie, positive values along the y-axis); countries on the right-hand side tend to be sources of migrants with HbS (ie, negative values along the y-axis). Uncertainties (based on the IQR) associated with the trends in migrants with HbS are shown in light red. The appendix shows plots for all countries. HbS=sickle-cell haemoglobin.
Figure 5
Figure 5
Estimated migration fluxes of individuals with HbS from Nigeria between 1960 and 2000 Thickness of the lines is proportional to the estimated number of HbS migrants to a given country. N=estimated number of net migrants with HbS. n=the number of countries to which individuals migrated. HbS=sickle-cell haemoglobin.
Figure 6
Figure 6
Estimated migration fluxes of individuals with HbS to the USA and the UK from 1960 to 2000 The thickness of the lines is proportional to the proportion of HbS migrants from a specific country amongst the total number of HbS immigrants. N=the estimated number of net migrants with HbS. n=the number of countries from which individuals migrated. HbS=sickle-cell haemoglobin.

References

    1. Özden Ç, Parsons CR, Schiff M, Walmsley TL. Where on earth is everybody? The evolution of global bilateral migration 1960–2000. June, 2011. (accessed Jan 1, 2014).
    1. Davis KF, D'Odorico P, Laio F, Ridolfi L. Global spatio-temporal patterns in human migration: a complex network perspective. PloS One. 2013;8:e53723.
    1. WHO . The world health report 2007—a safer future: global public health security in the 21st century. World Health Organization; Geneva: 2007.
    1. Gushulak B, Weekers J, Macpherson D. Migrants and emerging public health issues in a globalized world: threats, risks and challenges, an evidence-based framework. Emerg Health Threats J. 2009;2:e10.
    1. Zimmerman C, Kiss L, Hossain M. Migration and health: a framework for 21st century policy-making. Plos Med. 2011;8:e1001034.
    1. Rechel B, Mladovsky P, Ingleby D, Mackenbach JP, McKee M. Migration and health in an increasingly diverse Europe. Lancet. 2013;381:1235–1245.
    1. Bedford T, Cobey S, Beerli P, Pascual M. Global migration dynamics underlie evolution and persistence of human influenza A (H3N2) PLoS Pathog. 2010;6:e1000918.
    1. Stoddard ST, Morrison AC, Vazquez-Prokopec GM. The role of human movement in the transmission of vector-borne pathogens. PLoS Negl Trop Dis. 2009;3:e481.
    1. Tatem AJ, Huang Z, Das A, Qi Q, Roth J, Qiu Y. Air travel and vector-borne disease movement. Parasitology. 2012;139:1816–1830.
    1. Angastiniotis M, Vives-Corrons JL, Soteriades E, Eleftheriou A. The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders. Sci World J. 2013;2013:727905.
    1. Modell B, Bulyzhenkov V. Distribution and control of some genetic disorders. World Health Stat Q. 1988;41:209–218.
    1. Keinan A, Clark AG. Recent explosive human population growth has resulted in an excess of rare genetic variants. Science. 2012;336:740–743.
    1. Giordano PC. Prospective and retrospective primary prevention of hemoglobinopathies in multiethnic societies. Clin Biochem. 2009;42:1757–1766.
    1. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann N Y Acad Sci. 2005;1054:18–24.
    1. WHO . Fifty-ninth World Health Assembly: resolutions and decisions, annexes (WHA59/2006/REC/1) World Health Organization; Geneva: 2006.
    1. Serjeant GR. Geographic hetereogeneity of sickle cell disease. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Disorders of hemoglobin. 1st edn. Cambridge University Press; Cambridge: 2001. pp. 895–905.
    1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018–2031.
    1. Allison AC. The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria. Trans R Soc Trop Med Hyg. 1954;48:312–318.
    1. Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. BMJ. 1954;1:290–294.
    1. Livingstone FB. Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6PD variants, and ovalocytosis in human populations. Oxford University Press; New York: 1985.
    1. Piel FB, Patil AP, Howes RE. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104.
    1. Mednick LW, Orans M. The sickle-cell gene: migration versus selection. Am Anthropologist. 1956;58:293–295.
    1. Pante-de-Sousa G, Mousinho-Ribeiro RD, dos Santos EJM, Zago MA, Guerreiro JF. Origin of the hemoglobin S gene in a northern Brazilian population: the combined effects of slave trade and internal migrations. Genet Mol Biol. 1998;21:427–430.
    1. Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med. 2010;38(4 suppl):S512–S521.
    1. Lemos Cardoso G, Farias Guerreiro J. African gene flow to north Brazil as revealed by HBB*S gene haplotype analysis. Am J Hum Biol. 2006;18:93–98.
    1. King L, Fraser R, Forbes M, Grindley M, Ali S, Reid M. Newborn sickle cell disease screening: the Jamaican experience (1995–2006) J Med Screen. 2007;14:117–122.
    1. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115:4331–4336.
    1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79:704–712.
    1. Weatherall DJ. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol. 2011;154:736–744.
    1. Streetly A, Clarke M, Downing M. Implementation of the newborn screening programme for sickle cell disease in England: results for 2003–2005. J Med Screen. 2008;15:9–13.
    1. Parsons CR, Skeldon R, Walmsley TL, Winters LA. Quantifying international migration: a database of bilateral migrant stocks. World Bank; Washington, DC: 2007.
    1. Piel FB, Patil AP, Howes RE. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142–151.
    1. Hardy GH. Mendelian proportions in a mixed population. 1908. Science. 2003;76:79–80.
    1. Weinberg W. On the demonstration of heredity in man. Jahresh Wuertt Verh Vaterl Naturkd. 1908;64:369–382. (in German).
    1. R Core Team . R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna: 2012.
    1. Cataldo F. Immigration and changes in the epidemiology of hemoglobin disorders in Italy: an emerging public health burden. Ital J Pediatr. 2012;38:32.
    1. Roberts I, de Montalembert M. Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe. Haematologica. 2007;92:865–871.
    1. Dickerhoff R, Genzel-Boroviczeny O, Kohne E. Haemoglobinopathies and newborn haemoglobinopathy screening in Germany. J Clin Pathol. 2009;62:34.
    1. Wonkam A, Ponde C, Nicholson N, Fieggen K, Ramessar R, Davidson A. The burden of sickle cell disease in Cape Town. S Afr Med J. 2012;102:752–754.
    1. Theodorsson E, Birgens H, Hagve TA. Haemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in a Scandinavian perspective. Scand J Lab Clin Invest. 2007;67:3–10.
    1. Teoh Y, Greenway A, Savoia H, Monagle P, Roy J, Barnes C. Hospitalisations for sickle-cell disease in an Australian paediatric population. J Paediatr Child Health. 2013;49:68–71.
    1. Gergen PJ, Macri CJ, Murrillo S. The need for sickle cell screening among pediatric latino immigrants. Arch Pediatr Adolesc Med. 2002;156:729.
    1. Grosse SD, Olney RS, Baily MA. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl Health Econ Health Pol. 2005;4:239–247.
    1. Patch C. Newborn screening policy in the United Kingdom & the United States: two different communities of practice. MCN Am J Matern Child Nurse. 2006;31:164–168.
    1. Jans SM, van El CG, Houwaart ES. A case study of haemoglobinopathy screening in the Netherlands: witnessing the past, lessons for the future. Ethn Health. 2012;17:217–239.
    1. Bardakdjian-Michau J, Bahuau M, Hurtrel D. Neonatal screening for sickle cell disease in France. J Clin Pathol. 2009;62:31–33.
    1. Voskaridou E, Ladis V, Kattamis A. A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Ann Hematol. 2012;91:1451–1458.
    1. Kyrri AR, Felekis X, Kalogerou E. Hemoglobin variants in Cyprus. Hemoglobin. 2009;33:81–94.
    1. Colombatti R, Montanaro M, Guasti F. Comprehensive care for sickle cell disease immigrant patients: a reproducible model achieving high adherence to minimum standards of care. Pediatr Blood Cancer. 2012;59:1275–1279.
    1. Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopathies: progress and challenges. Transl Res. 2013;161:293–306.
    1. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84:323–327.
    1. Alswaidi FM, O'Brien SJ. Premarital screening programmes for haemoglobinopathies, HIV and hepatitis viruses: review and factors affecting their success. J Med Screen. 2009;16:22–28.
    1. Cao A, Galanello R. Effect of consanguinity on screening for thalassemia. New Engl J Med. 2007;9:372–377.
    1. AlHamdan NA, AlMazrou YY, AlSwaidi FM, Choudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med. 2007;9:372–377.
    1. Odame I, Kulkarni R, Ohene-Frempong K. Concerted global effort to combat sickle cell disease: the first global congress on sickle cell disease in Accra, Ghana. Am J Prev Med. 2011;41(6 Suppl 4):S417–S421.
    1. Hardison RC, Chui DH, Giardine B. A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Human Mutation. 2002;19:225–233.
    1. McBride KL, Snow K, Kubik KS. Hb Dartmouth [alpha66(E15)Leu-→Pro (alpha2) (CTG→CCG)]: a novel alpha2-globin gene mutation associated with severe neonatal anemia when inherited in trans with Southeast Asian alpha-thalassemia-1. Hemoglobin. 2001;25:375–382.
    1. Raymer J, Smith PWF. Modelling migration flows. J R Stat Soc. 2010;173:703–705.
    1. Abel GJ. Estimation of international migration flow tables in Europe. J R Stat Soc. 2010;173:797–825.
    1. Bijak J, Wiśniowski A. Bayesian forecasting of immigration to selected European countries by using expert knowledge. J R Stat Soc. 2010;173:775–796.
    1. Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr. 2000;136:201–208.
    1. Prior JF, Bittles AH, Erber WN. A community profile of alpha thalassaemia in Western Australia. Community Genet. 2004;7:211–215.
    1. Rezaee AR, Banoei MM, Khalili E, Houshmand M. Beta-thalassemia in Iran: new insight into the role of genetic admixture and migration. SciWorld Jnal. 2012;2012:635183.
Uncited Reference
    1. Gushulak BD, MacPherson DW. The basic principles of migration health: population mobility and gaps in disease prevalence. Emerg Themes Epidemiol. 2006;3:3.

Source: PubMed

3
Abonnieren